Drug Profile
H5N1 influenza virus vaccine intranasal - National Resilience
Alternative Names: GelVac™ nasal influenza vaccineLatest Information Update: 18 Jun 2021
Price :
$50
*
At a glance
- Originator DelSite Biotechnologies
- Developer National Resilience
- Class Influenza A virus H5N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Influenza-virus-infections in USA (Intranasal, Powder)
- 02 Oct 2017 Nanotherapeutics is now called as Ology Bioservices
- 20 Apr 2016 This programme is still active